Management

Chief Executive Officer since 2019

Kristina has 30 years of experience in drug development from leading roles in the pharmaceutical and biopharma industry. She has previously worked at AstraZeneca with research and development in both early and late phase and has been globally responsible for marketed products. Kristina has also worked at the biopharma company Albireo AB/Pharma Inc, as VP Clinical & Regulatory Affairs and VP Global Project Head and was engaged in building the company.

Shareholdings and warrants:
26 000 shares
Warrants granting acquisition rights to:
16 000 shares (warrants serie TO3)
53 000 shares (2020/2023, incentive program)

Education: MSc Pharmacy, PhD in Clinical Pharmacology

Other assignments: Board member of GU Ventures

Chief Scientific Officer since 2015

Anders is one of Alzinova’s co-founders and was also CEO of the Company during a transitional period. He has extensive experience in protein research with an emphasis on neurotoxic peptide devices. Anders has since 2007 worked with the ALZ-101 and ALZ-201 projects as its main occupation, and as chief operating officer has run much of the Company’s operations since it was founded in 2011. He is also a co-inventor of Alzinova’s AβCC technology and has been a deputy board member since 2011.

Shareholdings and warrants:
167 693 shares
Warrants granting acquisition rights to:
10 500 shares (2020/2023, incentive program)

Education: PhD in Chemistry

Other assignments: –

Chief Financial Officer since 2020

Håkan has more than 25 years of experience from leading finance positions in the shipping industry. He has previously worked as CFO and CEO at a privately owned Swedish shipping company with international operations where he has been involved in building the company. Håkan worked as CFO for Safe at Sea AB. Håkan also works as financial consultant for small and medium-sized companies.

Shareholdings and warrants:
16 000 shares
Warrants granting acquisition rights to:
8 000 shares (warrants serie TO3)
21 000 shares (2020/2023, incentive program)

Education: BSc Business and Economics, Small business management

Other assignments: –

Chief Medical Officer since 2019

Anders has more than 30 years of experience in drug development in both preclinical and phase I-IV clinical studies, as well as registration work on intra-EU approved medicines. He has worked at MSD Sweden, held leading positions at AstraZeneca and as Senior Global Director at Boehringer Ingelheim GmbH & Co KG in Germany, medically leading a large number of cardiovascular projects at various stages.

Shareholdings and warrants: –

Education: Licensed Physician, specialist in thoracic surgery. Associate Professor and Doctor of Medicine.

Other assignments: –

Business Development Director since 2023

Sebastian has 15 years of experience from pharmaceutical R&D and clinical development, CRO:s and GMP production of APIs (Active Pharmaceutical Ingredients). He has extensive experience in startups and business development. Before joining Alzinova he has been Chief Operating Officer at SWIPP AB, project manager and Key Account Manager at Polypeptide Group and Business development manager at Solve R&C.

Shares: 7 000

Education: MSc in Chemistry, PhD in Molecular Biophysics, MBA, Certified Board Member.

Development Project Director since 2021

Stefan has 25 years experience of drug discovery and development. He has worked as a pre-clinical research manager and early clinical project leader to bring compounds for clinical testing and beyond.  Stefan worked at AstraZeneca in different project leading and managerial roles in research and development. He also works as a senior consultant supporting smaller biotech and drug development companies

Shareholdings and warrants:
2 025 shares
Warrants granting acquisition rights to:
900 shares (warrants serie TO3)

Education: MSc Chemical Engineering, PhD Molecular Biology

Other assignments: CEO, ESP Life Science Consulting AB

Clinical Project Director since 2022